Chaitra Ujjani, MD
Hematology & Oncology · Seattle, WANPI 1598820763
Payments from drug & device makers
Across 240 payments — averaging $44,153 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacyclics LLC, An Abbvie Company$4.5M
- AbbVie$4.1M
- Eli Lilly$1.7M
- AstraZeneca$92K
- Gilead$74K
- ADC Therapeutics America, Inc.$26K
- plus $55K from 14 others
Across 16 payments — averaging $907.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$11K
- F. Hoffmann-la Roche AG$2K
- Gilead$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | 49 | $4,483,895 |
| AbbVie | 60 | $4,141,205 |
| Eli Lilly | 14 | $1,724,978 |
| AstraZeneca | 25 | $91,765 |
| Gilead(2 entities) | 16 | $74,274 |
| ADC Therapeutics America, Inc. | 19 | $25,593 |
| Beigene USA, Inc. | 9 | $6,962 |
| Verastem, Inc. | 9 | $6,647 |
| Astrazeneca UK Limited | 2 | $5,169 |
| Adaptive Biotechnologies Corporation | 1 | $4,400 |
| Genmab U.S., Inc. | 10 | $4,354 |
| Epizyme, Inc. | 4 | $4,106 |
| Genentech, Inc. | 3 | $3,988 |
| Incyte Corporation | 3 | $3,760 |
| Genentech USA, Inc. | 6 | $3,492 |
| Bristol Myers Squibb | 2 | $3,125 |
| Janssen Scientific Affairs, LLC | 3 | $3,028 |
| Johnson & Johnson | 2 | $2,890 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,768 |
| Seagen Inc. | 2 | $320 |
How this compares
$10,596,717 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Seattle
- Mazyar ShadmanSeattle$36.8M
- Ryan CassadaySeattle$22.7M
- John PesandoSeattle$15.7M
- Andrew CowanSeattle$15M
- Stephen SmithSeattle$12.6M
- Stephanie LeeSeattle$11.2M
- Sara HurvitzSeattle$10.9M
- Lawrence FongSeattle$9.7M
- Cameron TurtleSeattle$8.2M
- Ryan LynchSeattle$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.